Traditionally, cardiologists have focused on managing heart conditions through medication and lifestyle interventions, but with the growing evidence surrounding the benefits of managing glucose levels and visceral adipose tissue (VAT) loss, there has been a shift towards more integrated care. This includes incorporating treatments like GLP-1 mimetics into the broader strategy for patients with cardiovascular disease and metabolic conditions. For patients with coronary artery disease, heart failure, or atrial fibrillation, reducing visceral fat and improving glycaemic control can have a profound impact on both symptom management and long-term prognosis. In this blog article and podcast we discuss what is involved.

Full blog story